A5048659945- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Infectious Disease Case Reports and Treatments
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Biomedical Ethics and Regulation
- Immune Response and Inflammation
- CRISPR and Genetic Engineering
- Mycobacterium research and diagnosis
- Cancer Genomics and Diagnostics
- Leptospirosis research and findings
- Clostridium difficile and Clostridium perfringens research
- Acute Myeloid Leukemia Research
- Microbial infections and disease research
- Streptococcal Infections and Treatments
- Virus-based gene therapy research
- Hematopoietic Stem Cell Transplantation
- vaccines and immunoinformatics approaches
Fred Hutch Cancer Center
2016-2024
Washington State University
2013-2014
Universidade Federal de Pelotas
2007
Abstract Invariant Natural Killer T (iNKT) cells are a unique subset of innate lymphocytes, constituting <1% human cells. iNKT express semi-invariant TCR (iTCR) recognizing glycolipids presented by the monomorphic, MHC-like molecule CD1d. Previous studies indicate that due to distinctive constitution and antigen recognition properties, do not induce acute graft-versus-host disease. Based on CD4 CD8 expression, mature can be classified into CD4+CD8-, CD4-CD8- & CD4-CD8+ subsets...
Although allogeneic hematopoietic stem cell transplantation (HCT) can cure patients with chemotherapy-refractory acute myeloid leukemia (AML), post-HCT relapse remains common and extremely challenging to resolve. T immunotherapy could augment HCT efficacy by inducing deeper remissions pre-HCT prevent relapse, or treat post-HCT. However, development of for AML has been limited a paucity antigens established be safe effective targets. Recurrent AML-specific somatic variants, such as fusion...
149 Background: Allogeneic hematopoietic stem cell transplantation (HCT) often cures acute leukemia. However leukemic relapse remains a major cause of HCT failure, and patients with post-HCT have very poor prognosis. We are developing T immunotherapies targeting leukemia-associated minor histocompatibility (H) antigens to manage relapse. Because the presentation H is HLA-restricted, panel hematopoietic-restricted, required enable development broadly applicable antigen targeted immunotherapy....